RemeGen (HKG:9995, SHA:688331) reported a net loss attributable to shareholders of 291.0 million yuan for the quarter ended Sept. 30, according to a Tuesday filing with the Hong Kong bourse.
The loss per share for the quarter was 0.54 yuan.
Revenue was 467.1 million yuan, a 34.60% increase from the prior-year quarter.
Hong Kong shares of the biopharmaceutical company gained 3% in morning trade Wednesday, while its Shanghai shares gained nearly 4%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。